Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Notes Payables (2019 - 2020)

Protalix BioTherapeutics has reported Notes Payables over the past 2 years, most recently at $4.1 million for Q4 2020.

  • Quarterly results put Notes Payables at $4.1 million for Q4 2020, down 5.0% from a year ago — trailing twelve months through Dec 2020 was $4.1 million (down 5.0% YoY), and the annual figure for FY2020 was $4.1 million, down 5.0%.
  • Notes Payables for Q4 2020 was $4.1 million at Protalix BioTherapeutics, down from $4.3 million in the prior quarter.
  • Over the last five years, Notes Payables for PLX hit a ceiling of $4.3 million in Q4 2019 and a floor of $4.1 million in Q4 2020.